Hackensack, New Jersey 07601


High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant recipients worldwide for the same or similar disorders.

Study summary:

Many patients with multiple myeloma receive 2 stem cell transplantations within a few months of each other as part of their treatment. Usually the drug Melphalan is used for both transplants. Bortezomib is a drug that is used for treating multiple myeloma and has been used in combination with melphalan for stem cell transplantation for patients with multiple myeloma. The purpose of this trial is to study the effects of doing 2 transplants, first using melphalan and second using melphalan and bortezomib. The trial is aiming to find out if adding the Bortezomib to the second transplant will increase the chances of staying in remission longer.


Changed from: Inclusion Criteria: - Confirmed diagnosis of multiple myeloma with either Durie-Salmon stage I, II, or III or ISS stage I, II or III, less than 12 months since initiation of systemic therapy - ≥8x106 CD34+cells/kg available in cryopreservation in aliquots appropriate for tandem transplants - Age: 18-75 years at time of transplantation - KPS 70-100% - Recovery from complications of prior therapies - Gender: There is no gender restriction Exclusion Criteria: - Diagnosis other than multiple myeloma - Chemotherapy or radiotherapy within 8 days of initiating treatment in this study - Prior autologous or allogeneic transplantation (except as enrolled into this study) - Uncontrolled bacterial, viral, fungal or parasitic infections



Primary Contact:

Principal Investigator
Michele Donato, MD
John Theurer Cancer Center at Hackensack University Medical Center

Michele Donato, MD
Phone: 551-996-5900
Email: Michele.Donato@HackensackMeridian.org

Backup Contact:


Location Contact:

Hackensack, New Jersey 07601
United States

Marifiel Vendivil, RN
Phone: 551-996-5828
Email: Marifiel.Vendivil@HackensackMeridian.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.